Intech Investment Management LLC Sells 135,679 Shares of Omnicell, Inc. $OMCL

Intech Investment Management LLC cut its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 72.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 52,568 shares of the company’s stock after selling 135,679 shares during the quarter. Intech Investment Management LLC owned 0.12% of Omnicell worth $1,601,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Omnicell during the 2nd quarter valued at $26,000. First Horizon Corp bought a new stake in Omnicell in the third quarter valued at $31,000. Farther Finance Advisors LLC raised its holdings in shares of Omnicell by 784.8% during the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after purchasing an additional 1,036 shares during the period. LSV Asset Management bought a new position in shares of Omnicell during the 3rd quarter worth about $97,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Omnicell by 385.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on OMCL shares. Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. Wall Street Zen cut Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Piper Sandler reissued an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Wells Fargo & Company upped their price objective on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Finally, Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus price target of $54.50.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.52% of the stock is currently owned by corporate insiders.

Omnicell Stock Performance

Shares of OMCL stock opened at $42.25 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The firm has a 50-day moving average of $44.71 and a 200-day moving average of $38.20. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.00. The company has a market cap of $1.92 billion, a P/E ratio of 1,056.51, a P/E/G ratio of 1.49 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.